A dispensable role of PPARγ in rosiglitazone-mediated sensitization of human renal cancer cells to TRAIL-induced apoptosis was also demonstrated using a dominant-negative mutant of PPARγ [11]. This evidence concerns the gene PPARG and renal carcinoma.